Regorafenib

Brand Name: Stivarga

Manufacturer: Bayer

Indication
Regorafenib is indicated for patients with mCRC who have previously received and progressed on or after the following treatments:

Fluoropyrimidine-based chemotherapy
Oxaliplatin
Irinotecan
An anti-VEGF (vascular endothelial growth factor) therapy (e.g., bevacizumab)
If their cancer is RAS wild-type, an anti-EGFR (epidermal growth factor receptor) therapy (e.g., cetuximab or panitumumab)

Specific CRC Subtype: None

Stage: IV

Therapy Line: Third-line or later

Health Canada Approval: Approved

pCPA Negotiation Status: Not pursued

Reimbursed in:

New Search